Skip to main content
[Preprint]. 2020 Sep 24:rs.3.rs-80404. [Version 1] doi: 10.21203/rs.3.rs-80404/v1

Figure 4.

Figure 4

Pre-exposure prophylaxis with EIDD-2801, a broad-spectrum anti-coronavirus drug, potently prevents SARS-CoV-2 infection in vivo. a, Experimental design. LoM were administered EIDD-2801 or vehicle control 12 h prior to SARS-CoV-2 exposure and every 12 h thereafter. Virus titers in human lung tissues were measured 2 days post-exposure. b and c, SARS-CoV-2 titers in the human lung tissue of LoM administered EIDD-2801 (n=8 per experiment, yellow) or control vehicle (Ctrl, n=8 per experiment, blue) at 2 days post-exposure in two independent experiments shown b, separately and c, combined. Titers were compared with a two-tailed Mann-Whitney U test. Horizontal and vertical lines represent the median and interquartile range respectively. d, Fold difference in SARS-CoV-2 titers in the human lung tissue of LoM relative to vehicle controls. e, H&E staining and f, immunohistochemical staining for virus nucleoprotein (positive cells, brown) of human lung tissue of LoM administered EIDD-2801 (n=8 analyzed) or control vehicle (Ctrl, n=8 analyzed) at 2 days post-exposure (scale bars, 100 um).